The Retrospective Analysis Of Metformin’s Therapeutic Effect For Endometrial Cancer Patients With Diabetes Mellitus

Objective:At present a large number of studies have demonstrated the antitumor effects of metformin, which can lower the risk of cancer in diabetic patients and reduce all-cause mortality and improve survival outcomes in diabetic patients with cancer. This study aims to evaluate the effect of metformin on overall survival in patients with endometrial cancer and diabetes,by collecting the clinical and pathological data of patients with endometrial cancer and diabetes and conducting a retrospective analysis.And thus we can investigate the clinical value of metformin on these patients.Materials and Method:1.Data collectionSelect patients with endometrial cancer and diabetes who was treated at the Qilu Hospital of Shandong University from January 1998 to December 2008 for the study. All patients were diagnosed with diabetes and were pathologically confirmed endometrial cancer.In addition to associated with other serious diseases and lost cases, a total of 151 cases of patients (22% of all endometrial cancer patients) with complete follow-up data was included in the study,of which 56%(85/151 cases) use metformin and 44%(66/151 cases) did not use metformin.2. Methods:1. Collect the clinical and pathological data of all the 151 patients, and record the survival outcomes by the method of telephone follow-up. Up to December 2015,the mean follow-up was 70 months (9-84months). According to the condition being treated all subjects were divided into two groups:using metformin treatment group and not using metformin. Basic information between the two groups of patients has no significant statistical difference:1.Menopausal status and body mass index between the two groups has no significant statistical difference; 2.Two groups of patients have no significant statistical difference in tumor histological grade and FIGO stage; 3.Endometrial cancer histological type has no significant statistical difference between the two groups of patients, are mainly endometrioid carcinoma; 4.In addition to metformin,there was no significant statistical difference in the adjuvant therapies betwwen the two groups. Through the survival conditions of the two groups of patients were analyzed retrospectively, overall survival was evaluated and thus to observe the effect of metformin on outcomes of endometrial cancer combined diabetes treatment.3. Statistical analysisUsing SPSS 17.0 software package for statistical analysis. Measurement data used chi-square test for statistical analysis; P<0.05 indicates a significant difference. Survival curves were plotted using the Kaplan-Meier method and Survival curves were compared using Log-rank test.Results:In the two groups, metformin users have significantly improved overall survival. Metformin users had a median survival time of 82 months (95%CI:72.017-91.983), while non-metformin users had a median survival time of 62 months (95%CI: 51.389-72.611).The mortality of metformin users was 57.6% and non-metformin users was 77.3%, P= 0.003.Conclusion:Metformin can obviously improve the overall survival and reduce all-cause mortality in patients with diabetes and endometrial cancer, indicating that metformin in the treatment of cases of endometrial cancer and diabetes are of value clinically. But the specific dose and the degree of improvement also need to be detected in large samples.